Top

Published in:

01-02-2013 | Melanomas

Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women

Authors: Robert H. I. Andtbacka, MD, CM, Matthew R. Donaldson, MD, Tawnya L. Bowles, MD, Glen M. Bowen, MD, Kenneth Grossmann, MD, PhD, Hung Khong, MD, Douglas Grossman, MD, PhD, Christopher Anker, MD, Scott R. Florell, MD, Anneli Bowen, MD, Keith L. Duffy, MD, Sancy A. Leachman, MD, PhD, R. Dirk Noyes, MD

Published in: Annals of Surgical Oncology | Issue 2/2013

Abstract

Background

The incidence of melanoma is rising in young women of childbearing age. Melanoma diagnosed during pregnancy presents unique challenges. This study was conducted to determine the effect of sentinel lymph node biopsy (SLNB) for melanoma on maternal and fetal outcomes in pregnant women.

Methods

A prospective melanoma database was retrospectively queried for women diagnosed with melanoma during or immediately before pregnancy as well as SLNB in pregnant women. The outcomes of SLNB for the mothers and fetuses were evaluated.

Results

Fifteen pregnant women underwent wide local excision (WLE) and SLNB for melanoma from 1997 to 2012. The median gestational age was 20 weeks. More than half of the women noticed changes in the primary melanoma lesion during the pregnancy. The median Breslow thickness was 1.00 mm. Lymphatic mapping and SLNB were performed with some combination of radiocolloid or vital blue dye without adverse effects. Three patients had micrometastatic disease and underwent a completion lymphadenectomy. Sixteen children were born at a median gestational age of 39 weeks. The median 1- and 5-minute Apgar scores were 8 and 9, respectively. At a median follow-up of 54.4, months none of the patients had experienced recurrence, and all children were healthy and free of melanoma.

Conclusions

In this series of pregnant women with melanoma, SLNB was performed safely during pregnancy without adverse effects to the mothers and fetuses. We recommend that clinicians explain the risks and benefits of the SLNB procedure to pregnant women so an informed decision can be made about the procedure.

American Cancer Society. Melanoma Skin Cancer Overview. Revised January 23, 2012. http://www.cancer.org/acs/groups/cid/documents/webcontent/003063-pdf.pdf (January 23, 2012).

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRef

Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults. J Invest Dermatol. 2008;128:2905–8.PubMedCrossRef

Schwartz JL, Mozurkewich EL, Johnson TM. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer. 2003;97:2130–3.PubMedCrossRef

Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011;104:379–85.PubMed

Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.PubMedCrossRef

National Comprehensive Cancer Network. NCCN guidelines, melanoma. Version 3. 2012.

Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Compr Canc Netw. 2009;7:308–17.PubMed

Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14:250–4.PubMedCrossRef

10.

Mondi MM, Cuenca RE, Ollila DW, Stewart JH IV, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol. 2007;14:218–21.PubMedCrossRef

11.

Gentilini O, Cremonesi M, Toesca A, et al. Sentinel lymph node biopsy in pregnant patients with breast cancer. Eur J Nucl Med Mol Imaging. 2010;37:78–83.PubMedCrossRef

12.

Gentilini O, Cremonesi M, Trifirò G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004;15:1348–51.PubMedCrossRef

13.

Lewis KD, Gonzalez R, Robinson WA, Fitzpatrick JE, McCarter MD, Braden C. A young woman with melanoma diagnosed during pregnancy. Oncology (Williston Park). 2004;18:794–9.

14.

Broer N, Buonocore S, Goldberg C, et al. A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol. 2012;106:36–40.PubMedCrossRef

15.

U.S. Census Bureau. American community survey 2008 (table S1301) and special tabulations. http://www.census.gov/hhes/fertility/data/cps/2008.html (January 30, 2012).

16.

Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol. 2003;21:2179–86.PubMedCrossRef

17.

Alexander A, Harris RM, Grossman D, Bruggers CS, Leachman SA. Vulvar melanoma: diffuse melanosis and metastasis to the placenta. J Am Acad Dermatol. 2004;50:293–8.PubMedCrossRef

18.

Thompson JA. The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol. 2002;29:361–9.PubMedCrossRef

19.

Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.PubMedCrossRef

20.

Apgar V. Proposal for new method of evaluation of newborn infant. Anesth Analg. 1953;32:260–7.CrossRef

21.

Casey BM, McIntire DD, Leveno KJ. The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med. 2001;344:467–71.PubMedCrossRef

22.

Walton NKD, Melachuri VK. Anaesthesia for non-obstetric surgery during pregnancy. Contin Educ Anaesth Crit Care Pain. 2006;6:83–5.CrossRef

23.

Karakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg. 1994;81:1771–4.PubMedCrossRef

24.

Morita ET, Chang J, Leong SPL. Principles and controversies in lymphoscintigraphy with emphasis on breast cancer. Surg Clin North Am. 2000;80:1721–39.PubMedCrossRef

25.

Cimmino VM, Brown AC, Szocik JF, et al. Allergic reactions to isosulfan blue during sentinel node biopsy—a common event. Surgery. 2001;130:439–42.PubMedCrossRef

26.

Montgomery LL, Thorne AC, Van Zee KJ, et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth Analg. 2002;95:385–8.PubMed

27.

Raut CP, Hunt KK, Akins JS, et al. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol. Cancer. 2005;104:692–9.PubMedCrossRef

28.

Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500.PubMedCrossRef

29.

Komenaka IK, Bauer VP, Schnabel FR, et al. Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J. 2005;11:70–2.PubMedCrossRef

30.

Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–6.PubMedCrossRef

31.

Bézu C, Coutant C, Salengro A, Daraï E, Rouzier R, Uzan S. Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol. 2011;20:e55–9.PubMedCrossRef

32.

Cragen JD. Teratogen update: methylene blue. Teratology. 1999;60:42–8.CrossRef

33.

Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMedCrossRef

34.

Gershenwald JE, Tseng CH, Thompson W, Mansfield PF, Lee JE, Bouvet M. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998;124:203–10.PubMedCrossRef

35.

McMasters KM, Wong SL, Edwards MJ, et al. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery. 2001;130:151–6.PubMedCrossRef

36.

McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: how many radioactive nodes should be removed? Ann Surg Oncol. 2001;8:192–97.PubMedCrossRef

37.

Andtbacka RHI, Grissom CB, Boucher K, et al. Fluorescein identifies sentinel lymph nodes safely and precisely in patients with stage I and II cutaneous melanoma. The 7th International Sentinel Node Society meeting, Yokohama, Japan, November 19, 2010.

38.

Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;15;106:237–46.CrossRef

39.

Chan MP, Chan MM, Tahan SR. Melanocytic nevi in pregnancy: histologic features and Ki-67 proliferation index. J Cutan Pathol. 2010;37:843–51.PubMedCrossRef

40.

O’Meara AT, Cress R, Xing G, Danielsen B, Smith LH. Malignant melanoma in pregnancy. A population-based evaluation. Cancer. 2005;103:1217–26.PubMedCrossRef

41.

Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47:2607–17.PubMedCrossRef

42.

Jhaveri MB, Driscoll MS, Grant-Kels JM. Melanoma in pregnancy. Clin Obstet Gynecol. 2011;54:537–45.PubMedCrossRef

43.

Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node–positive melanoma. J Clin Oncol. 2006;24:2858–65.PubMedCrossRef

44.

Hauschild A, Gogas H, Tarhini A, et al. Practical guidelines for the management of interferon-alfa-2b side effects in patients receiving adjuvant treatment for melanoma. Cancer. 2008;112:982–93.PubMedCrossRef

45.

MacKie RM, Bufalino R, Morabito A, Sutherland C, Cascinelli N. Lack of effect of pregnancy on outcome of melanoma. Lancet. 1991;337:653–5.PubMedCrossRef

Title: Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women
Authors: Robert H. I. Andtbacka, MD, CM
Matthew R. Donaldson, MD
Tawnya L. Bowles, MD
Glen M. Bowen, MD
Kenneth Grossmann, MD, PhD
Hung Khong, MD
Douglas Grossman, MD, PhD
Christopher Anker, MD
Scott R. Florell, MD
Anneli Bowen, MD
Keith L. Duffy, MD
Sancy A. Leachman, MD, PhD
R. Dirk Noyes, MD
Publication date: 01-02-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 2/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2633-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Sentinel Lymph Node Biopsy for Melanoma in Pregnant Women

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

Illness-Related Distress in Women with Clinically Localized Cutaneous Melanoma

A Comparison of Surgical Morbidity and Scar Appearance Between Gasless, Transaxillary Endoscopic Thyroidectomy (GTET) and Minimally Invasive Video-Assisted Thyroidectomy (VAT)

Intraoperative Diagnosis Using Sentinel Node Biopsy with Indocyanine Green Dye in Gastric Cancer Surgery: An Institutional Trial by Experienced Surgeons

High Expression of Patched Homolog-1 Messenger RNA and Glioma-Associated Oncogene-1 Messenger RNA of Sonic Hedgehog Signaling Pathway Indicates a Risk of Postresection Recurrence of Hepatocellular Carcinoma

Intestinal-type and Pancreatobiliary-type Adenocarcinomas: How Does Ampullary Carcinoma Differ from Other Periampullary Malignancies?

Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States